PulseAugur
LIVE 04:07:15
research · [1 source] · · 中文(ZH) “星锐医药”完成近4000万美元B+轮融资
0
research

Starry Pharma raises $40M for cell therapy, Uncharted Dynamics secures seed funding

Starry Pharma has secured nearly $40 million in Series B+ funding, with participation from investors including Hillhouse Ventures, LYFE Capital, and Lilly Asia Ventures. The capital will accelerate clinical development for its in vivo CAR-T therapies and expand its mRNA innovation efforts. Separately, Uncharted Dynamics, a company focused on embodied AI infrastructure, raised a seed round of several million dollars led by Summit Ascent, to fund R&D for its high-precision dynamics solver and North American expansion. AI

Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →

IMPACT These funding rounds will advance AI infrastructure and therapeutic development, potentially accelerating innovation in embodied AI and cell-based treatments.

RANK_REASON The cluster contains two distinct funding rounds for AI-related companies, one of which is a significant amount for a Series B+ round. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on 36氪 (36Kr) →

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Star-Sharp Pharma Completes Nearly $40 Million Series B+ Financing

    36氪获悉,“星锐医药”宣布完成近4000万美元B+轮融资。本轮融资由产业基金联合高瓴创投、LYFE Capital (洲嶺资本)、礼来亚洲基金(LAV)、夏尔巴投资、源码资本及春华资本共同参投。本次募集资金将重点用于加速体内细胞治疗(in vivo CAR-T) 多条管线的临床开发进程、推进肺部、肠道及神经系统等肝外递送平台的搭建,巩固并强化公司在mRNA治疗领域的创新研发布局。